Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986158 and BMS-986378 in Pediatric Cancer
NCT03936465Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of 2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol and trotabresib in solid tumor, lymphoma and brain tumor, sponsored by Dana-Farber Cancer Institute. Started Sep 2019; status: completed.
02
Drugs
2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-oltrotabresib
03
Conditions
solid tumorlymphomabrain tumor
Beyond the preview
Go deeper on NCT03936465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03936465.